Table 3.
Control group | Intervention group | P | |||
---|---|---|---|---|---|
Sex |
|
%(n) |
|
|
0.75a |
|
Women |
|
68.7 (121) |
59.2(103) |
|
|
Men |
|
31.3(55) |
40.8(71) |
|
|
Overall |
|
100(176) |
100.0(174) |
|
Mean ± SD |
|
|
|
||
Age (years) |
83.3 ± 6.9 |
80.8 ± 7.3 |
0.001b |
||
Weight (kg) |
65.5 ± 12.1 |
66.8 ± 12.0 |
0.335b |
||
Height (m) |
1.6 ± 0.1 |
1.6 ± 0.1 |
0.069b |
||
BMI (Kg/m2) |
26.1 ± 4.0 |
26.3 ± 3.8 |
0.721b |
||
SBP (mm Hg) |
130.7 ± 17.3 |
134.7 ± 18.7 |
0.060b |
||
DBP (mm Hg) |
71.5 ± 11.3 |
75.0 ± 12.3 |
0.012b |
||
Creatinine (mg/dl) |
1.1 ± 0.4 |
1.2 ± 0.8 |
0.052b |
||
Body surface (m2) |
1.7 ± 0.2 |
1.7 ± 0.2 |
0.162b |
||
GFR (ml/min/1.73 m2) |
61.7 ± 16.5 |
60.7 ± 17.0 |
0.572b |
||
CrCl (ml/min) |
45.0 ± 12.1 |
45. + ±13.0 |
0.525b |
||
CrCl-BS (ml/min/1.73 m2) |
46.3 ± 11.6 |
47.1 ± 12.6 |
0.550b |
||
Total number of drugs per patient |
7.3 ± 2.9 |
6.3 ± 3.2 |
0.003b |
||
Drugs with restriction in RI per patient |
4.0 ± 2.0 |
3.5 ± 2.1 |
0.069b |
||
Number of DRP per patient |
0.7 ± 1.0 |
0.5 ± 1.0 |
0.164b |
||
Prevalence of DI (%) |
17.5 ± 28.2 |
15.5 ± 29.1 |
0.514b |
||
Comorbidity %(n) |
|
|
|
||
Hypertension |
72.2(127) |
69.5(121) |
0.639a |
||
T2DM |
23.9(42) |
11.5(20) |
0.003a |
||
Dyslipidemia |
39.8(70) |
37.4(65) |
0.662a |
||
Hyper/Hypo Thyroidism |
5.7(10) |
6.3(11) |
0.826a |
||
CVD |
30.7(54) |
23.6(41) |
0.150a |
||
CKD | 10.2(18) | 8.0(14) | 0.579a |
Abbreviations: BMI Body Mass Index, SBP Systolic Blood Pressure, DBP, Diastolic Blood Pressure, T2DM Type 2 Diabetes Mellitus, CVD Cardiovascular Disease, CKD Chronic Kidney Disease, GFR Rate of Glomerular filtration, CrCl Creatinine Clearance, CrCl-BS Creatinine Clearace adjusted to body surface, RI renal impairment, DRP Drug-related problem, DI Dosing inadequacy, Drugs with restrictions (dose adjustment needed in case of renal impairment (RI)) per patient [20-22], SD Standard deviation.
aχ2Test.
b T Student test for independent groups.